bortezomib and vorinostat in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large b-cell lymphoma

Conditions: Recurrent Mantle Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma

Summary: this phase ii trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large b-cell lymphoma. bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

this was a multicenter, non-randomized phase 2 trial using a simon two-stage design with 3 cohorts. primary objectives: i. estimate the response rates of mantle cell and diffuse large b-cell lymphomas to bortezomib and vorinostat combination therapy. secondary objectives: i. assess the safety and tolerability of the study regimen. ii. observe progression-free survival and response durations. iii. observe the relationship between pretreatment lymphoma cell nuclear v-rel reticuloendotheliosis viral oncogene homolog a (rela) and response. outline: patients receive vorinostat orally (po) once daily (qd) on days 1-5 and 8-12. patients also receive bortezomib intravenously (iv) over 3-5 seconds on days 1, 4, 8, and 11. courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * histologically confirmed mantle cell or diffuse large b-cell lymphoma; histological material must be available for central pathological review; unstained histological material -- slides or blocks -- must be available for correlative studies; archived material from previous biopsies is acceptable, unless a patient's lymphoma has been known to undergo histological transformation in the past, in which case a repeat biopsy to confirm histology prior to enrollment is required; availability of material must be confirmed at the time of registration, but material may be submitted subsequent to registration and initiation of study treatment * measurable disease according to the revised response criteria for malignant lymphoma; this requires at least one lesion greater than 1.0 cm in diameter in both the long and short axis as measured by spiral computed tomography (ct) scan or physical exam * prior allogeneic stem cell transplant is allowed provided that all of the following conditions are met: * \>= 6 months have elapsed since allogeneic transplant * no graft vs. host disease (gvhd) is present * not currently on immunosuppressive therapy * prior therapy: * mantle cell lymphoma: * previously treated or untreated * no prior bortezomib * diffuse large b-cell lymphoma: * at least one prior systemic therapy * no prior bortezomib * note: not intended for patients in first relapse who are candidates for high dose therapy with stem cell support * life expectancy of greater than 3 months * eastern cooperative oncology group (ecog) performance status 0, 1, or 2 * able to tolerate loperamide or other anti-diarrheal medications * absolute neutrophil count \>= 1.5 x 10\^9/l * platelets \>= 75 x 10\^9/l * total bilirubin =\< 1.5 x upper limit of normal (uln) * aspartate aminotransferase (ast) (serum glutamic oxaloacetic transferase \[sgot\])/alanine aminotransferase (alt) (serum glutamate pyruvate transaminase \[sgpt\]) =\< 2.5 x institutional upper limit of normal * creatinine within normal institutional limits or calculated creatinine clearance \>= 60 ml/min according to the cockcroft-gault formula * for patients with known human immunodeficiency virus (hiv) infection, a cluster of differentiation (cd)4 count \>= 0.5 x 10\^9/l * for patients whose last treatment included bendamustine or fludarabine, a cd4 count \>= 0.4 x 10\^9/l * women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and to report pregnancy or suspected pregnancy while participating in the study * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * chemotherapy or large field radiotherapy within 3 weeks prior to entering the study * prior histone deacetylase inhibitor as cancer treatment * concurrent treatment with other investigational agents * plans for other concurrent cancer treatment; if steroids for cancer control have been used, patients must be off these agents for \>= 1 week before starting treatment; exception: maintenance therapy for non-malignant disease with prednisone or steroid equivalent dose \< 10 mg/day is permitted * history of brain metastasis including leptomeningeal metastasis * grade \>= 2 neuropathy, regardless of cause * unable to take oral medications * history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib or vorinostat * not sufficiently recovered from previous treatment * medical or other condition (for example: uncontrolled infection; potentially life threatening changes on electrocardiogram \[ekg\]) or concurrent treatment (for example, marrow suppressive agents such as zidovudine) that represents an inappropriate risk to the patient or likely would compromise achievement of the primary study objective; patients should be closely monitored when given bortezomib in combination with the cytochrome p450, family 3, subfamily a, polypeptide 4 (cyp3a4) inhibitors and inducers * pregnant women are excluded from this study; breastfeeding should be discontinued * active concurrent malignancy, except adequately treated non-melanoma skin cancer